Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results on November 15, 2021 FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID–19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expected in Second [...] Read more »